Alendronate should be considered as an alternative therapy of osteogenesis imperfecta (OI) because it significantly increased areal bone mineral density (BMD) and its Z score, decreased fracture incidence, inhibited bone resorption biomarkers. Alendronate exerted beneficial roles in different age brackets, especially in young patients with OI.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
99
Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme.LTD.).
changes from baseline of areal BMD at lumbar spine and total hip
Time frame: baseline and 12,24,36 months
annual clinical fracture incidence
Time frame: baseline and 12,24,36 months
changes of bone turnover biomarkers
Time frame: baseline and 6,12,24,36 months
changes of height
Time frame: baseline and 12,24,36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.